RAPPERSWIL, Switzerland, Sept. 15, 2017 /CNW/ - Alexandre Sudarskis, Chief Executive Officer (CEO) of Neovii Pharmaceuticals will step down as CEO having reached retirement age. Neovii Pharmaceuticals appointed Juergen Pohle, Chief Commercial Officer, as CEO and Managing Director of Neovii as of January 1, 2018.
(Logo: http://mma.prnewswire.com/media/527086/Neovii_Pharmaceuticals_Logo.jpg)
(Photo: http://mma.prnewswire.com/media/556703/Juergen_Pohle.jpg)
(Photo: http://mma.prnewswire.com/media/556702/Alexandre_Sudarskis.jpg)
CEO since June 2014, Alexandre Sudarskis established Neovii Pharmaceuticals’ headquarters in Switzerland and has played a leading role in the launch of GRAFALON®, the restructuring and globalization of the company. Further Alexandre lead the activities to broaden the portfolio which included in-licensing certain rights to ARCALYST®.
Mr. Sudarskis commented: “Neovii has significantly expanded with increasing performance, paving the way to become a recognized player in transplantation medicine.” He will continue to support Neovii as Executive Director and member of Neovii Pharmaceuticals Board.
David Fuhrer, Chairman, says: “Our special thanks go to the outgoing Managing Director Alexandre Sudarskis. Under his leadership, the turnaround of the company was successfully completed and business was expanded into new territories.”
Juergen Pohle has served as Chief Commercial Officer of Neovii Pharmaceuticals since March 2016, where he was responsible for the company’s global business. He draws on over 25 years of experience in the pharmaceutical industry at Bayer HealthCare, GSK and Novartis. Most recently he was heading the business for Emerging Growth Markets and Institutional Customers like UNICEF for Novartis Vaccines and Diagnostics AG in Basel. He is a German citizen, married and has one child.
David Fuhrer commented: “Juergen’s leadership skills, his long-term proven track record and his many years of international experience in the pharmaceutical industry make him the ideal candidate for the position of CEO. We are extremely pleased that Juergen has embraced the challenge of further driving the development and growth of Neovii.”
Juergen Pohle added: “I feel very honored and humbled to have been giving the opportunity to lead Neovii and would like to thank Alexandre for his mentorship during the last years. Furthermore, I wish to express my gratitude to David for the trust I have been granted. We will continue to develop Neovii to become a leading provider of life-saving, innovative drugs in the transplantation and rare diseases area.”
About Neovii
Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.
Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders.
Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Massachusetts, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.
For further information
For further information, please visit: http://www.neovii.com
SOURCE Neovii Pharmaceuticals AG
